NVIDIA launches Jetson Thor robotics computers for physical AI systems
William Jacob Savage, the Chief Medical (TASE:BLWV) Officer at Disc Medicine, Inc. (NASDAQ:IRON), has sold a portion of his holdings in the company. According to a recent filing, Savage sold 6,677 shares of common stock on May 20, 2025. The shares were sold at a weighted average price of $50.0417, resulting in a total transaction value of approximately $334,128. The transaction occurred near the stock’s current trading price of $48.04, with the company currently valued at $1.67 billion. According to InvestingPro data, IRON’s stock has shown significant volatility, with a 52-week range of $30.82 to $68.73. Following this sale, Savage retains 59,721 shares in the company. The transaction was executed under a Rule 10b5-1 trading plan established in November 2024. Analysts maintain a strong bullish stance on IRON, with a consensus recommendation of 1.36 (Strong Buy). InvestingPro analysis reveals 8+ additional key insights about IRON’s financial health and future prospects, available exclusively to subscribers through the comprehensive Pro Research Report.
In other recent news, Disc Medicine has been the focus of several analyst updates and strategic developments. Cantor Fitzgerald maintained its Overweight rating on the company, keeping a 12-month price target of $99. This decision was based on updated financial models that reflect the company’s recent public offering and revised operating expense estimates. Meanwhile, Scotiabank (TSX:BNS) raised its price target for Disc Medicine to $75, citing the company’s plans to submit a New Drug Application for bitopertin in 2025 and its solid financial position following a capital raise. The company is also preparing for a phase 3 trial of bitopertin, which could lead to a 2026 launch if priority review is granted by the FDA.
TD Cowen initiated coverage on Disc Medicine with a Buy rating, highlighting the potential of bitopertin to penetrate the erythropoietic protoporphyria (EPP) market, which is significantly larger than initially assumed. Additionally, TD Cowen pointed out the underappreciated market potential of the company’s treatment 0974 in the myelofibrosis anemia space, estimating it to be nearly a $1 billion opportunity. The chronic kidney disease market, expected to be validated this year, presents another significant opportunity for the company. These recent developments indicate a promising outlook for Disc Medicine’s drug pipeline and strategic market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.